Thymidylate Kinase-Targeted Antimicrobial Peptides via Phage Display: A Novel Strategy against Gram-Negative Bacteria

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL Journal of Medicinal Chemistry Pub Date : 2025-02-25 DOI:10.1021/acs.jmedchem.4c02666
Mingyang Hu, Yuwen Li, Lu Zhao, Sina Cha, Yuxin Fang, Chenyu Xue, Na Dong
{"title":"Thymidylate Kinase-Targeted Antimicrobial Peptides via Phage Display: A Novel Strategy against Gram-Negative Bacteria","authors":"Mingyang Hu, Yuwen Li, Lu Zhao, Sina Cha, Yuxin Fang, Chenyu Xue, Na Dong","doi":"10.1021/acs.jmedchem.4c02666","DOIUrl":null,"url":null,"abstract":"The rise of antimicrobial resistance (AMR) in Gram-negative bacteria, including <i>Escherichia coli</i> (<i>E. coli</i>), poses a major public health threat. This study aimed to address the limitations of existing antimicrobial peptides (AMPs) by designing hybrid peptides with enhanced targeting and antibacterial potency. Eight heptapeptide sequences were identified through phage display screening and hybridized with WP (WKKIWKPGIKKWIK), a peptide exhibiting weak antimicrobial activity against Gram-negative bacteria. The hybrid peptides were systematically evaluated for their antimicrobial activity, specificity, and biocompatibility. The hybrid peptide SWP exhibited superior antibacterial activity, particularly against <i>E. coli</i> K88 (TI = 2.378), and demonstrated specific binding to thymidylate kinase (TMK), a key bacterial enzyme. <i>In vivo</i> studies employing a mouse peritonitis model confirmed SWP’s ability to reduce bacterial loads and mitigate tissue damage while maintaining excellent biocompatibility. These findings underscore SWP as a promising candidate for the development of targeted antimicrobial agents with enhanced specificity and stability for Gram-negative pathogens.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"31 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02666","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

The rise of antimicrobial resistance (AMR) in Gram-negative bacteria, including Escherichia coli (E. coli), poses a major public health threat. This study aimed to address the limitations of existing antimicrobial peptides (AMPs) by designing hybrid peptides with enhanced targeting and antibacterial potency. Eight heptapeptide sequences were identified through phage display screening and hybridized with WP (WKKIWKPGIKKWIK), a peptide exhibiting weak antimicrobial activity against Gram-negative bacteria. The hybrid peptides were systematically evaluated for their antimicrobial activity, specificity, and biocompatibility. The hybrid peptide SWP exhibited superior antibacterial activity, particularly against E. coli K88 (TI = 2.378), and demonstrated specific binding to thymidylate kinase (TMK), a key bacterial enzyme. In vivo studies employing a mouse peritonitis model confirmed SWP’s ability to reduce bacterial loads and mitigate tissue damage while maintaining excellent biocompatibility. These findings underscore SWP as a promising candidate for the development of targeted antimicrobial agents with enhanced specificity and stability for Gram-negative pathogens.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过噬菌体展示胸苷激酶靶向抗菌肽:一种对抗革兰氏阴性菌的新策略
包括大肠杆菌在内的革兰氏阴性细菌抗菌素耐药性(AMR)的上升构成了重大的公共卫生威胁。本研究旨在通过设计具有增强靶向性和抗菌效力的杂交肽来解决现有抗菌肽的局限性。通过噬菌体展示筛选鉴定出8个七肽序列,并与抗菌活性较弱的肽WP (WKKIWKPGIKKWIK)进行杂交。系统地评估了杂交肽的抗菌活性、特异性和生物相容性。该杂化肽SWP对大肠杆菌K88 (TI = 2.378)具有较强的抗菌活性,并能特异性结合胸苷酸激酶(TMK)。采用小鼠腹膜炎模型的体内研究证实了SWP能够减少细菌负荷和减轻组织损伤,同时保持良好的生物相容性。这些发现强调SWP是开发针对革兰氏阴性病原体具有更高特异性和稳定性的靶向抗菌药物的有希望的候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
期刊最新文献
Computational Design, Synthesis, and Evaluation of Stapled Peptide-Based Antagonists of the CGRP Receptor. Exploiting a Cryptic Pocket in DsbA through Structure-Guided Parallel Synthesis and Direct-to-Biology Screening Structure-Based Discovery of a New LpxH-Targeted Chemotype with Activity against Klebsiella pneumoniae. Nitroimidazole-Containing [68Ga]Ga-IPM-N001 as a New CAIX-Targeting Radionuclide Tracer. Development of Dihydroquinoxalinone-Based Dual CDK6/BET Inhibitors for Triple-Negative Breast Cancer Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1